Tag Archives: Politics

Merkel ally says Turkey’s Erdogan ‘not welcome’ in Germany

Turkish President Tayyip Erdogan makes a speech during a meeting in Istanbul, Turkey, March 19, 2017. REUTERS/Murad Sezer

By Andrea Shalal

BERLIN (Reuters) – Turkish President Tayyip Erdogan has crossed a line by comparing Berlin’s government to the Nazis and he and other officials are no longer welcome in Germany, a senior ally of Chancellor Angela Merkel said on Tuesday.

The rebuke from Volker Bouffier, vice chairman of Merkel’s Christian Democratic Union (CDU) party, reflects growing exasperation over Erdogan’s assertions that Germany and other European powers were using Nazi tactics by banning Turkish political rallies in their territories.

“Enough is enough,” said Bouffier, who is also premier of Hesse state where the financial capital Frankfurt is located. “Mr. Erdogan and his government are not welcome in our country, and that must be now be understood,” he told DLF radio.

German media have reported that Erdogan plans to visit Germany this month to rally the estimated 1.4 eligible Turkish voters living here to support a package of new presidential powers in an April 16 referendum.

Bouffier said such a visit would create security problems. “Someone who insults us in this way cannot expect that we will assemble thousands of police to protect him,” he said.

Germany’s government has said it has not received a formal request for a visit by Erdogan.

On Monday, Merkel once again called on Turkey to stop the Nazi comparisons and said Berlin reserved the right to block future appearances by Turkish officials if they did not comply with German law, which explicitly forbids malicious disparagement of the government.

Foreign Minister Sigmar Gabriel said the diplomatic note in which Berlin approved further visits by Turkish politicians had an explicit reference to the German law against disparagement.

“If that happens, and there are violations of our laws, then will have to … revoke the note” and approvals of various visits, Gabriel told reporters after a meeting with EU Commission Vice President Frans Timmermans.

Timmermans said EU officials were united in rejecting the Nazi comparisons. “President Erdogan’s comments about Germany and the Netherlands are not allowed. We don’t want to be compared to Nazis,” he said.

Erdogan repeated his criticism of Germany and other European countries on Tuesday, saying today’s “fascist and cruel” Europe resembled the pre-World War Two era.

In Istanbul on Sunday, he said, “Merkel, now you’re applying Nazi methods. Against my brothers who live in Germany, and against my ministers and lawmakers who visit there.”

Reiner Haseloff, another member of Merkel’s CDU and premier of Saxony-Anhalt state, urged Berlin to bar such visits.

“Those who compare us to Nazis are not welcome. That is not acceptable,” he told Die Welt newspaper in an article published on Tuesday. He said Berlin should not rely on local and state governments to make decisions about visits by Turkish politicians as it has up to now.

In his speech on Tuesday, Erdogan said Turkey could no longer be pressured by considerations such as a $6 billion migrant deal under which it agreed to stop illegal migrants from crossing into Greece in exchange for financial aid and accelerated EU membership talks.

EU Commissioner Johannes Hahn told the Bild newspaper in an interview published Tuesday that Turkey’s prospects for joining the EU would be “increasingly unrealistic” unless it changed course and stopped moving away from European values.

Hahn said the EU had repeatedly voiced its concerns about the “increasingly authoritarian path of President Erdogan.”

“Threats are no way to make policies. They make a reasonable dialogue impossible,” he said.

(Reporting by Gernot Heller, Andrea Shalal and Reuters TV in Berlin, and Tuvan Gumrukcu and Ece Toksabay in Istanbul; Editing by Tom Heneghan)

Russia must limit Iranian power in Syria: Israeli intelligence director

FILE PHOTO: Russian President Vladimir Putin (R) meets with Israeli Prime Minister Benjamin Netanyahu in Moscow, Russia, March 9, 2017. Sputnik/Mikhail Klimentyev/Kremlin via REUTERS/File Photo

By Luke Baker

JERUSALEM (Reuters) – Russia and other world powers must move to limit Iran’s growing military strength in Syria because it poses a regional threat, the director-general of Israel’s Intelligence Ministry told Reuters in an interview.

Israeli officials estimate Iran commands at least 25,000 fighters in Syria, including members of its own Revolutionary Guard, Shi’ite militants from Iraq and recruits from Afghanistan and Pakistan. It also coordinates the activities of the powerful Lebanese militia Hezbollah.

“As we speak, relations between Iran and Syria are getting tighter,” said Chagai Tzuriel, the top civil servant in Israel’s Intelligence Ministry, who spent 27 years in Mossad, including as station chief in Washington.

“Iran is in the process of putting together agreements, including economic agreements, with Syria to strengthen its hold, its ports and naval bases there,” he said in a rare interview. “There is a need for Russia and other powers to work to avoid the threat that Iran ends up with military, air and naval bases in Syria.”

Israel has long warned about the threat from Iran, especially its perceived desire to acquire nuclear weapons, but now sees a rising territorial squeeze, with Tehran’s influence reaching in an arc from Lebanon in the north to Gaza in the south, where it has links to Islamist groups.

Iran maintains it wants a nuclear capability only for domestic energy and scientific research purposes, and has so far largely stuck to the terms of the nuclear deal agreed with the United States and other world powers in 2015.

Tzuriel said the conflict in Syria, now in its seventh year, had created a number of imbalances in the region – whether between Sunni and Shi’ite Muslims, Iran and Turkey, Kurds and Arabs, Turkey and Syria, Russia and the United States – that needed to be kept contained and shifted back into equilibrium.

A lot of the responsibility for that rests with Russia, which has become the biggest player in the region and is capable of exerting the most influence, he said.

“When it comes to Iran, the United States, Russia and other powers need to understand that (growing Iranian influence in Syria) is going to be a constant source of friction,” said Tzuriel, adding that it could reduce Moscow’s own influence in the region and set back the gains it has made in Syria.

“Russia has a vested interest in keeping that threat contained.”

‘WHAT DO WE WANT?’

Israeli Prime Minister Benjamin Netanyahu has met President Vladimir Putin five times since Sept. 2015, largely in an effort to ensure communications are open and there are no misunderstandings over Syria, where Israeli fighter planes have occasionally bombed targets, including last week. Syria fired a missile in response and Moscow called in Israel’s ambassador to discuss the Israeli raid.

“We don’t view Russia as the enemy and I don’t think they view us as the enemy either,” said Tzuriel, but he suggested Russia would need to work with others, including the United States, to keep a lid on the forces at play in Syria.

“We have to assume that the Russians want stability, they want a Pax Russiana in the region,” he said.

“If they want a stabilization, they can’t do it alone. They need the United States, they need regional powers, they need opposition parties and militias, even those that are not exactly Russia’s cup of tea.”

After a career in intelligence gathering, Tzuriel drew a distinction between intelligence and strategy. After years of conflict and more than 500,000 dead, it was still incumbent on the parties tied to Syria to fix a strategic outcome.

“We have to decide what we want (in Syria) or what we don’t want,” he said. “The main strategic threat right now is what happens in Syria, it is the key arena. There’s no place in the world that has so many elements wrapped up in it.”

(Writing by Luke Baker; Editing by Pravin Char)

France’s Fillon fights on as window closes for putting up alternative candidate

FILE PHOTO: Francois Fillon, former French prime minister, member of The Republicans political party and 2017 presidential election candidate of the French centre-right, attends a meeting at the Trocadero square across from the Eiffel Tower in Paris, France, March 5, 2017. REUTERS/Philippe Wojazer/File Photo

By John Irish

PARIS (Reuters) – Scandal-hit Francois Fillon is set to be confirmed as the conservative candidate in France’s presidential election on Friday as the window for putting an alternative name on the ballot paper closes.

The campaign is one of the most unpredictable in the country’s history as almost 40 percent of voters have yet to make their final choice amid a topsy-turvy campaign dominated by a fraud investigation into Fillon.

Once the frontrunner, the former prime minister has fought off pressure from his The Republicans party to step aside before Friday’s deadline when all presidential candidates must be formally endorsed by at least 500 elected officials.

His main rival for the party ticket, Alain Juppe, opted not to challenge him, even if theoretically he could still get 500 backers by 1800 local time (1700 GMT).

Fillon, 63, has faced down his critics and insisted he will fight on despite an Odoxa opinion poll on Friday showing that three-quarters of French voters want him to pull out of the race.

The fraud investigation into Fillon widened on Thursday to include luxury suits he received as gifts. He was already placed under formal investigation earlier in the week on suspicion of misusing public funds linked to salaries he paid his wife and children.

Fillon, far-right leader Marine Len Pen, independent centrist Emmanuel Macron, Socialist candidate Benoit Hamon, far-left firebrand Jean-Luc Melenchon and two lesser-known candidates have already reached the endorsement target.

Another four at least could also reach the goal when the Constitutional Council publishes its final sponsors list.

It will confirm the candidates on Saturday.

Melenchon categorically ruled out on Friday quitting the election race in favour of Hamon.

Since news of the Fillon scandal emerged on January 25, he has tumbled from being the favorite to third place in opinion polls, a position that would eliminate him in the first round on April 23.

The polls point to a May 7 run-off between Le Pen and Macron, with the latter convincingly winning that duel.

A weekly Ipsos SopraSteria poll for Le Monde on Friday showed Fillon losing more ground to Le Pen and Macron.

(Reporting by John Irish; Editing by Adrian Croft)

South Korea to hold election May 9, prosecutors summon ousted Park

South Korea's ousted leader Park Geun-hye greets her supporters as she arrives at her private home in Seoul, South Korea, March 12, 2017. REUTERS/Kim Kyung-Hoon

By Christine Kim and Ju-min Park

SEOUL (Reuters) – South Korea said on Wednesday it will hold an election on May 9 to choose a successor for former President Park Geun-hye, who was removed from office in a historic court ruling last week over a widening corruption scandal.

Prosecutors said on Wednesday Park – the first democratically elected president to be removed from office in South Korea – would be summoned for questioning on Tuesday into the influence-peddling scandal.

The Constitutional Court dismissed Park from office on Friday when it upheld a parliamentary impeachment vote in December.

Park has denied any wrongdoing.

The Samsung Group [SAGR.UL], South Korea’s largest conglomerate, is already embroiled in the scandal and the Yonhap news agency said prosecutors had started investigating two other conglomerates – the Lotte Group and SK Group.

Samsung denies any wrongdoing. Spokesman for both the SK Group and Lotte said they would cooperate with the investigation.

The turmoil comes at a time of rising tension with North Korea over its nuclear and missile programs, and with China over the deployment of a U.S. anti-missile system in South Korea that China sees as a threat to its security.

U.S. Secretary of State Rex Tillerson will visit South Korea, as well as Japan and China, this week.

Prime Minister Hwang Kyo-ahn, who has been acting president since the impeachment vote, said he would not run in the election.

Minister of the Interior Hong Yun-sik promised the vote would be the most clean and transparent ever.

“This election is unprecedented in our history,” Hong told a briefing, referring to the short campaign period.

Hwang had emerged in opinion polls as a top conservative candidate even though he had not declared an intention to run.

The scandal has undermined support for the ruling conservatives, and Hwang’s decision would appear to bolster the chances of a prominent liberal, Moon Jae-in, who is leading in opinion polls.

‘FIND TRUTH’

Park was summoned to appear for questioning at 9.30 a.m. (0030 GMT) next Tuesday, the prosecutors’ office said.

Her lawyers said in a statement they would cooperate.

“The lawyers will cooperate with the investigation to find substantive truth swiftly by actively helping with various procedures,” they said.

Park had declined to be questioned by prosecutors or testify at the Constitutional Court when she was in office.

After she left the presidential Blue House on Sunday, she issued a statement hinting of defiance, saying: “It will take time, but I believe the truth will be revealed.”

Prosecutors have not said how long they think their investigation would last.

A special prosecution team had accused Park of colluding with a friend, Choi Soon-sil, to pressure big businesses into contributing to foundations set up to support her policies and allowing Choi to influence state affairs.

Choi also denied wrongdoing.

Jay Y. Lee, the head of Samsung Group, is on trial on bribery, embezzlement and other charges in connection with the scandal. Lee denies all charges.

The prospect of an opposition election victory has raised questions about the future in South Korea of the U.S.-made Terminal High Altitude Area Defense (THAAD) anti-missile system, which China opposes because it says its radar can penetrate its territory.

Tillerson will meet Hwang and Foreign Minister Yun Byung-se in Seoul on Friday. He is not scheduled to see opposition figures, a U.S. State Department official said, raising questions about the durability of any agreements.

The aircraft carrier the USS Carl Vinson is in South Korean waters this week for exercises with South Korean forces.

North Korea said the exercises were part of a “reckless scheme” to attack it and it warned the United States of “merciless” strikes if the carrier infringed on its sovereignty or dignity.

(Reporting by Ju-min Park and Christine Kim; Additional reporting by Se Young Lee, Hyunjoo Jin; Writing by Robert Birsel; Editing by Bill Tarrant)

Trump Middle East envoy meets Palestinian leader Abbas

Palestinian President Mahmoud Abbas meets with Jason Greenblatt, U.S. President Donald Trump's Middle East envoy, in the West Bank city of Ramallah, March 14, 2017. REUTERS/Mohamad Torokman

RAMALLAH, West Bank (Reuters) – U.S. President Donald Trump’s Middle East envoy held his first talks on Tuesday with Palestinian President Mahmoud Abbas, amid Palestinian concerns that the new administration in Washington is more favorably disposed toward Israel.

Jason Greenblatt’s talks with Abbas took place in Ramallah, the Palestinian seat of government, a day after he held a lengthy meeting with Israeli Prime Minister Benjamin Netanyahu in Jerusalem.

“President Abbas & I discussed how to make progress toward peace, building capacity of Palestinian security forces & stopping incitement,” Greenblatt tweeted after the meeting.

In a separate statement issued by the U.S. Consulate General, the two men “reaffirmed the commitment of both the Palestinian Authority and the United States to advance a genuine and lasting peace between Israel and the Palestinians”.

Abbas stressed that the Palestinian strategic choice was to achieve a two-state solution, the statement added.

Peace talks between Israel and the Palestinians have been frozen since 2014. Since his inauguration on Jan. 20, Trump has been ambivalent about a two-state solution, the mainstay of U.S. policy in the region for the past two decades.

“I’m looking at two-state and one-state, and I like the one that both parties like … I can live with either one,” Trump told a Feb. 15 news conference during a visit to Washington by Netanyahu, causing consternation across the Arab world and in many European capitals.

However, Trump last Friday held his first telephone conversation with Abbas since becoming president and invited him to the White House.

Tuesday’s statement said Abbas had told Greenblatt he believed that under Trump’s leadership “a historic peace deal was possible”.

Abbas and Greenblatt also discussed plans to strengthen the Palestinian economy and the importance of ensuring economic opportunities for Palestinians, the statement said.

On Monday, Netanyahu and Greenblatt discussed Israel’s settlement building “with the hope of reaching a formula that will aim to promote peace and security”, the Israeli leader’s office said.

One of the most heated issues between Israel and the Palestinians is Israel’s building of settlements in the occupied West Bank and East Jerusalem, territory the Palestinians want for their own future state along with the Gaza Strip.

Greenblatt, a longtime top lawyer in Trump’s company, also serves as the president’s special negotiator for trade deals, among other responsibilities.

(Reporting by Ori Lewis; Editing by Gareth Jones)

Trump chooses Gottlieb to run FDA; Pharma breathes sigh of relief

Dr. Scott Gottlieb is seen in this American Enterprise Institute photo released in Washington, DC, U.S., March 10, 2017. Courtesy The American Enterprise Institute/Handout via REUTERS

By Toni Clarke

WASHINGTON (Reuters) – U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday.

If confirmed by the Senate, Gottlieb would be in charge of implementing Trump’s plan to dramatically cut regulations governing food, drugs, cosmetics, dietary supplements and tobacco.

Gottlieb is well known on Capitol Hill, where he has testified multiple times on hot-button health issues, including complex drug pricing matters, and is viewed favorably by drug companies and pharmaceutical investors. He sits on the boards of several small drug and biotech companies and is an adviser to GlaxoSmithKline Plc <GSK.L>.

“Thank God it’s Gottlieb,” Brian Skorney, an investment analyst at Robert W. Baird, wrote in a research note. “We view this as a favorable development for the sector.”

Gottlieb was chosen over Jim O’Neill, a libertarian investor close to Silicon Valley billionaire Peter Thiel, a PayPal co-founder who now advises Trump on technology and science matters. O’Neill’s stated view that drugs should be approved before being proven effective generated widespread alarm.

Gottlieb, 44, is a resident fellow at the conservative American Enterprise Institute think tank and a partner at a large venture capital fund. He is a former FDA deputy commissioner who has advocated a loosening of requirements needed for approval of new medical products.

“Scott knows how the agency works and he will move it forwards, though maybe not always in ways the agency is comfortable with,” said John Taylor, a lawyer and president of compliance and regulatory affairs with the consulting firm Greenleaf Health and a former acting FDA deputy commissioner.

In addition to his public health and health policy roles, Gottlieb has for the past decade been a partner at New Enterprise Associates, a large venture fund with investments in the life sciences, medical technology and healthcare services.

Critics of the nomination say Gottlieb’s financial background present an array of potential conflicts of interest.

Dr. Michael Carome, director of Public Citizen’s Health Research Group, said Gottlieb “has spent most of his career dedicated to promoting the financial interests of the pharmaceutical industry.” If confirmed, he added, “he will have to be recused from key decisions time and time again.”

SIGNIFICANT CHANGES AT FDA EXPECTED

Stephen Ubl, a spokesman for the Pharmaceutical Research and Manufacturers of America, said it “looks forward to working with Dr. Gottlieb in his new role and engaging with him and the Agency as they seek to modernize the drug discovery and review process.”

Gottlieb, who declined to comment on the nomination, is unlikely to up-end the FDA in the way O’Neill might have, but he is nonetheless expected to bring significant change, including moving the agency to increase flexibility in the clinical trial development process.

In this he will be supported by the recently passed 21st Century Cures Act which instructs the FDA among other things to consider the use of “real world evidence” to support new drug applications. This could include anecdotal data, observational studies and patient reports

“People don’t want to take chances with safety, but there’s increasingly some clamor to be more flexible on the efficacy side,” said Kathleen Sanzo, who leads the FDA practice at the law firm Morgan, Lewis & Bockius. “You need to have some signal of efficacy. The question is, how much?”

The FDA has attempted to push back against moves to sideline randomized clinical trials, long considered the gold standard. In January it issued a report documenting 22 cases in which drugs that appeared to show promise in early trials turned out to be either ineffective or unsafe or both in larger trials.

One of Gottlieb’s priorities will likely be to streamline the process for approving generic versions of complex, difficult-to-copy therapeutics. He has stated publicly that he does not believe the FDA has good tools or policies to move such products and has advocated the creation of different approval standards.

“He’s a thoughtful and nuanced kind of guy, and not solely an industry shill,” said Jim Shehan, head of Lowenstein Sandler’s FDA regulatory practice.

A survey conducted by Mizuho Securities USA Inc of 53 pharmaceutical executives found that 72 percent favored Gottlieb over other potential candidates. Many described him as knowledgeable, experienced and balanced.

“Gottlieb is someone who the industry and investors view as an incremental positive,” said RBC Capital Markets analyst Michael Yee. “The industry and investors need rational scientific logic and an understanding of risks and benefits.”

Patient advocates welcomed the news.

Gottlieb “has firsthand experience at the FDA and as a physician that has treated patients understands the breadth of work that needs to be achieved on their behalf,” said Ellen Sigal, founder of Friends of Cancer Research.

(Reporting by Toni Clarke; Additional reporting by Deena Beasley; Editing by Alistair Bell and Lisa Shumaker)

Turkish tensions with Europe risk spilling into Switzerland

European Union (L) and Turkish flags fly outside a hotel in Istanbul, Turkey May 4, 2016. REUTERS/Murad Sezer/File Photo

By Michael Shields

ZURICH (Reuters) – Neutral Switzerland risks getting swept up in Turkey’s political row with European countries as Swiss authorities weigh how to handle Turks’ requests for asylum and a call to ban a rally on Sunday by Turkey’s foreign minister.

The government was keeping a low profile on Thursday, saying only that it was reviewing a request by financial capital Zurich to block a planned weekend appearance by Foreign Minister Mevlut Cavusoglu for security reasons.

The Hilton hotel booked for the rally canceled the event, saying organizers could not ensure the safety of guests and visitors.

It comes amid a series of speaking engagements to galvanize support among the Turkish community for President Tayyip Erdogan’s bid to increase his powers in a referendum on April 16.

The foreign ministry declined to comment on media reports that several Turks with diplomatic passports, including the second-ranking envoy in Bern, had sought asylum after President Tayyip Erdogan’s crackdown in the wake of a failed coup last year.

The State Secretariat for Migration, which handles asylum requests, said it does not comment on individual requests for refugee status. It referred instead to a government response this week to a parliamentary query on the matter.

That note said 408 Turkish citizens had sought asylum since the July coup attempt, including some holders of diplomatic passports. It said it could not comment further on the “very few individual cases” among diplomats for fear it could give away their identities.

Turkish embassy officials in Bern were not immediately available by phone and did not respond to an email seeking comment.

During a visit to neighboring Germany on Wednesday, Cavusoglu accused Berlin of hostility towards his country and Islam as acrimony between the NATO allies showed no sign of abating.

On Thursday, Chancellor Angela Merkel told Turkey to stop comparing the German government to the Nazis over the cancellation of Turkish ministers’ rallies in Germany, only for Cavusoglu to repeat the comparison.

Ankara is furious over the cancellations. Germany has said the rallies can go ahead if the organizers respect local laws, but has canceled several rallies, citing security concerns.

In Austria, the interior minister said this week he wanted to change legislation to permit a ban on foreign officials making speeches in Austria if human rights or public order were threatened, a move aimed at Turkish politicians.

Swiss government statistics show around 68,000 Turkish citizens live in Switzerland, a nation of 8.3 million whose population is a quarter foreign. The Turkish embassy’s website refers to around 130,000 Turkish citizens.

(Additional reporting by Brenna Hughes Neghaiwi; Editing by Hugh Lawson)

Berlin says Turkey has stepped up spying in Germany

Turkish Foreign Minister Mevlut Cavusoglu meets his German counterpart Sigmar Gabriel in Berlin, Germany, March 8, 2017. Cem Ozdel/Turkish Foreign Ministry Press Office/Handout via Reuters

BERLIN (Reuters) – The German government said on Wednesday there had been a significant increase in Turkish spying in Germany, where tensions within the large Turkish community have escalated ahead of next month’s referendum on Turkey’s presidency.

The BfV domestic intelligence agency said divisions in Turkey leading up to the April 16 referendum on boosting the powers of President Tayyip Erdogan were mirrored in Germany.

At the same time, strained relations between Germany and Turkey, which soured after a failed army bid last July to overthrow Erdogan, reached a new low this month in a row over Turkish political rallies to drum up support in the referendum.

“The BfV is observing a significant increase in intelligence efforts by Turkey in Germany,” it said in a statement. No further details were provided.

Germany’s chief federal prosecutor launched an investigation in January into possible spying by clerics sent to Germany by Ankara.

Bfv President Hans-Georg Maassen underscored his concern over tensions between right-wing Turks in Germany and supporters of the Kurdistan Workers Party (PKK).

“There is the danger that these proxy fights between PKK supporters and nationalist, right-wing extremist Turks will escalate because there is a high, hard-hitting potential for danger in both groups,” he said.

Maassen did not specifically address the issue of Turkish spying. He told reporters in January that Germany would not tolerate Turkish intelligence operations within its borders.

German Foreign Minister Sigmar Gabriel on Wednesday met his Turkish counterpart Mevlut Cavusoglu in Berlin and said Turkey’s internal fights should not be imported into Germany.

(Reporting by Sabine Siebold, Writing by Andrea Shalal; Editing by Dominic Evans)

House panels to launch fight in Congress over Obamacare replacement

(L-R)U.S. House Majority Leader Kevin McCarthy, U.S. House Speaker Paul Ryan, and U.S. Representative Greg Walden hold a news conference on the American Health Care Act on Capitol Hill in Washington, U.S. March 7, 2017. REUTERS/Eric Thayer

By David Lawder

WASHINGTON (Reuters) – A potentially lengthy U.S. legislative fight over replacement of the Obamacare health law gets underway on Wednesday as two House of Representatives committees begin negotiating over changes to a Republican plan backed by President Donald Trump.

Both Democrats and Republicans are expected to try to reshape legislation that dismantles key provisions of the 2010 Affordable Care Act, Democratic former President Barack Obama’s signature domestic policy achievement.

The Republican plan unveiled on Monday would scrap Obamacare’s requirement that most Americans obtain medical insurance and replace its income-based subsides with a system of fixed tax credits of $2,000 to $4,000 to coax people to purchase private insurance on the open market.

The plan faces significant hurdles in Congress. Conservative Republican lawmakers and lobbying groups slammed it for looking too much like the Obamacare program they have been trying to kill for years. Democrats criticized it as rolling back health insurance coverage gains for millions of Americans while benefiting the rich by repealing healthcare-related taxes.

Meanwhile, insurers questioned the assumptions underlying Republicans’ claims that the plan will reduce premiums, while some experts said it would encourage younger, healthier people to forgo coverage.

On Wednesday, The House Ways and Means Committee, with jurisdiction over taxes, and the House Energy and Commerce Committee, which oversees health issues, will each pursue separate “mark-up” sessions to consider amendments to the plan.

House Speaker Paul Ryan has pledged that he will deliver a 218-vote majority needed for passage in the House. But further changes could be made in the Senate, where Republicans can only afford to lose two votes from their thin majority in the face of unified opposition from Democrats.

Conservative Republican Senator Rand Paul on Tuesday declared the plan “dead on arrival” in broadcast interviews and said he wanted a repeal-only option.

House Ways and Means Committee Chairman Kevin Brady told Fox News Channel late on Tuesday that he would “listen to good ideas to improve it” but said the plan achieves the party’s goals.

“It repeals all the taxes, all the mandates, all the penalties, all the subsidies. This is Obamacare gone and there’s no arguing about that,” Brady said.

But he also said that much of the bill’s fate was in the Senate’s hands and he was “counting on” Senate Republicans to support it without major changes.

Trump, who praised the Republican healthcare plan but said it was “out for review and negotiation,” plans to meet conservative congressional leaders to discuss it on Wednesday, according to a schedule released by the White House.

In an evening Twitter message, Trump said he was “sure” that Senator Paul would “come along with the new and great healthcare program because he knows Obamacare is a disaster!”

(Corrects to say Monday, not Tuesday, in third paragraph.)

(Writing by David Lawder; Editing by Nick Tattersall, Robert Birsel)

Trump backs House healthcare plan, says open to negotiations

The federal government forms for applying for health coverage are seen at a rally held by supporters of the Affordable Care Act, widely referred to as "Obamacare", outside the Jackson-Hinds Comprehensive Health Center in Jackson, Mississippi, U.S. on October 4, 2013. REUTERS/Jonathan Bachman/File Photo

WASHINGTON (Reuters) – U.S. President Donald Trump on Tuesday backed a draft Republican proposal to dismantle Obamacare that was unveiled Monday, saying the proposed healthcare legislation was “out for review and negotiation.”

Trump, in a tweet on Tuesday morning, described the bill proposed by fellow Republicans in the House of Representatives as “Our wonderful new healthcare bill.”

The plan, released late on Monday, would undo Democratic President Barack Obama’s 2010 healthcare law, removing the penalty paid by Americans without insurance coverage and rolling back extra healthcare funding for the poor.

The plan was swiftly criticized by Democrats.

Although Obamacare has long been a common target of Republicans, the proposal also met with skepticism from some in the party who are concerned about the replacement plan’s tax credits for buying health insurance and changes to coverage under Medicaid, the government health insurance program for the poor.

The plan must pass both the Republican-led House of Representatives as well as the Senate, where it faces a higher bar for passage, making its future uncertain.

Trump was due to meet with the team of House lawmakers charged with tracking support for legislation later on Tuesday as lawmakers on two key House committees prepare to review the bill on Wednesday.

White House Office of Budget and Management Director Mick Mulvaney, speaking in a round of television interviews on Tuesday, said he expected the plan to pass the House before lawmakers leave for recess in mid-April.

Still, Obamacare remains popular with many Americans. Some 20 million previously uninsured Americans gained coverage under the law, although higher insurance premiums have angered some. Nearly half of those gained insurance under an expansion of Medicaid, which would end in 2020 under the Republicans’ new plan, then face funding caps.

Polls have shown most Americans want to maintain Medicaid’s expansion.

Some industry groups have also expressed concern that lawmakers are moving forward without knowing how much the new proposal will cost or how it will affect healthcare coverage. Mulvaney told CBS he expected the Congressional Budget Office’s review of the bill in a few days.

House Democratic leader Nancy Pelosi said on CBS program “This Morning” that the Republican plan would take millions of people off health insurance rolls. “Show us the numbers about what the impact is personally on people,” she said.

(Reporting by Susan Heavey and Doina Chiacu; Editing by Frances Kerry)